Chun Chen

Chun Chen started their work experience as a Manager at Shanghai Medicilon Inc. in 2018. In this role, they were responsible for designing and planning synthetic routes for synthesizing heterocyclics and oligonucleotides, as well as leading a team of over 45 chemists for synthetic FTE and FFS projects. They also managed and operated synthetic chemistry laboratories.

Next, Chun Chen worked as a Sr MedChem Scientist at Simcere Pharmaceutical Group from 2019 to 2021. Here, they served as a chemistry leader on cross-functional teams for kinase inhibitor projects, delivering one pre-clinical candidate nomination. They also had knowledge in multi-parameter optimization across potency, selectivity, and ADME properties.

After that, Chun Chen joined Insilico Medicine in 2021 as the Chemistry leader in Medicinal Chemistry. In this role, they served as a chemistry leader on cross-functional teams for cancer and solid tumor treatment projects, delivering one pre-clinical candidate nomination. Their expertise included knowledge in multi-parameter optimization across potency, selectivity, and ADME properties.

Most recently, Chun Chen has been working as a Principal Scientist at Kimia Therapeutics since 2023. Further details about this role were not provided.

Chun Chen holds a PhD in Synthetic Methodology and has expertise in the Total Synthesis of Natural Product from the University of Bristol. Chun also pursued a PDRA degree at Boston College, specializing in Catalysis, Multi-component Reaction, Copper Catalysis, and Boron Chemistry. Additionally, they obtained another PDRA degree from EPFL (École polytechnique fédérale de Lausanne), focusing on Hypervalent Iodine Reagents and Synthetic Methodology. However, specific start and end years for each educational experience were not provided.